| Ident. | Authors (with country if any) | Title |
|---|
| 000077 (2015) |
Yilong Ma [États-Unis] ; Tom H. Johnston [Canada] ; Shichun Peng [États-Unis] ; Chuantao Zuo [République populaire de Chine] ; James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Yihui Guan [République populaire de Chine] ; David Eidelberg [États-Unis] ; Jonathan M. Brotchie [Canada] | Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET. |
| 000122 (2015) |
Kaviraja Udupa [Canada] ; Susan H. Fox [Canada] | Placebo effect in Parkinson's disease: Harnessing the mind in the treatment of PD. |
| 000134 (2015) |
Susan H. Fox [Canada] ; Connie Marras | Orthostatic hypotension in Parkinsonism: What is it and how can we treat it? |
| 000294 (2015) |
Camila Catherine Aquino [Canada] ; Susan H. Fox | Clinical spectrum of levodopa-induced complications. |
| 000370 (2014) |
Camila C. Aquino [Canada] ; Susan H. Fox | Understanding conversion disorders: back to Freud's theory. |
| 000499 (2014) |
Isabelle Beaulieu-Boire [Canada] ; Susan H. Fox | New methods of preventing neurodegeneration? Lessons from prion diseases. |
| 000765 (2013) |
Kaviraja Udupa [Canada] ; Susan H. Fox | Subthalamic nucleus and striatum: the red and green signals to regulate the traffic of basal ganglia circuitry. |
| 000876 (2013) |
Lorraine V. Kalia [Canada] ; Jonathan M. Brotchie ; Susan H. Fox | Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials. |
| 000915 (2013) |
Susan H. Fox [Canada] | Metabolic disorders causing movement disorders in childhood; an addition to the list. |
| 000D50 (2012) |
Philippe Huot [Canada] ; Tom H. Johnston ; Naomi P. Visanji ; Tayyeba Darr ; Donna Pires ; Lili-Naz Hazrati ; Jonathan M. Brotchie ; Susan H. Fox | Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease. |
| 000D51 (2012) |
Susan H. Fox [Canada] | Improved viability of stem cell transplants in animal models of Parkinson's disease. |
| 000F18 (2012) |
Susan H. Fox [Canada] ; Tom H. Johnston ; Qin Li ; Jonathan Brotchie ; Erwan Bezard | A critique of available scales and presentation of the Non-Human Primate Dyskinesia Rating Scale. |
| 001089 (2012) |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Naomi P. Visanji [Canada] ; Tayyeba Darr [Canada] ; Donna Pires [Canada] ; Lili-Naz Hazrati [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Increased Levels of 5-HT1A Receptor Binding in Ventral Visual Pathways in Parkinson's Disease |
| 001237 (2012) |
Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; QIN LI [République populaire de Chine] ; Jonathan Brotchie [Canada] ; Erwan Bezard [République populaire de Chine, France] | A Critique of Available Scales and Presentation of the Non-Human Primate Dyskinesia Rating Scale |
| 001309 (2011) |
James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; Allan Goodman [États-Unis] ; Bertrand Le Bourdonnec [États-Unis] ; Roland E. Dolle [États-Unis] ; Robert N. Dehaven [États-Unis] ; Diane L. Dehaven-Hudkins [États-Unis] ; Patrick J. Little [États-Unis] ; Jonathan M. Brotchie [Canada] | The selective mu‐opioid receptor antagonist adl5510 reduces levodopa‐induced dyskinesia without affecting antiparkinsonian action in mptp‐lesioned macaque model of Parkinson's disease |
| 001350 (2011) |
Klaus Seppi [Autriche, Portugal] ; Daniel Weintraub [États-Unis] ; Miguel Coelho [Portugal] ; Santiago Perez-Lloret [France] ; Susan H. Fox [Canada] ; Regina Katzenschlager [Autriche] ; Eva-Maria Hametner [Autriche] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Christopher G. Goetz [États-Unis] ; Cristina Sampaio [Portugal] | The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease |
| 001351 (2011) |
Susan H. Fox [Canada] ; Regina Katzenschlager [Autriche] ; Shen-Yang Lim [Malaisie] ; Bernard Ravina [États-Unis] ; Klaus Seppi [Autriche] ; Miguel Coelho [Portugal] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Christopher G. Goetz [États-Unis] ; Cristina Sampaio [Portugal] | The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease |
| 001549 (2011) |
Arpan R. Mehta [Canada, Royaume-Uni] ; Susan H. Fox [Canada] ; Mark Tarnopolsky [Canada] ; Grace Yoon [Canada] | Mitochondrial mimicry of multiple system atrophy of the cerebellar subtype |
| 001944 (2010) |
Tom H. Johnston [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Juha-Matti Savola [Suisse] ; Jonathan M. Brotchie [Canada] | The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates |
| 001C27 (2010) |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Tayyeba Darr [Canada] ; Lili-Naz Hazrati [Canada] ; Naomi P. Visanji [Canada] ; Donna Pires [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Increased 5‐HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations |
| 001D22 (2010) |
Tom H. Johnston [Canada] ; Anne Van Der Meij [Pays-Bas] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Effect of histamine H2 receptor antagonism on levodopa–induced dyskinesia in the MPTP‐macaque model of Parkinson's disease |
| 001F06 (2010) |
Tom H. Johnston [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Juha-Matti Savola [Suisse] ; Jonathan M. Brotchie [Canada] | The α2 Adrenergic Antagonist Fipamezole Improves Quality of Levodopa Action in Parkinsonian Primates |
| 001F39 (2010) |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Tayyeba Darr [Canada] ; Lili-Naz Hazrati [Canada] ; Naomi P. Visanji [Canada] ; Donna Pires [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Increased 5-HT2A Receptors in the Temporal Cortex of Parkinsonian Patients with Visual Hallucinations |
| 002059 (2009) |
Susan H. Fox [Canada] ; Rosalind Chuang [Canada] ; Jonathan M. Brotchie [Canada] | Serotonin and Parkinson's disease: On movement, mood, and madness |
| 002578 (2008) |
Naomi P. Visanji [Canada] ; Rob M. A. De Bie [Canada, Pays-Bas] ; Tom H. Johnston [Canada] ; Andrew C. Mccreary [Pays-Bas] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson's disease |
| 002783 (2008) |
Susan H. Fox [Canada] ; Anthony E. Lang [Canada] | Levodopa‐related motor complications—Phenomenology |
| 002A35 (2008) |
Cindy Zadikoff [États-Unis, Canada] ; Susan H. Fox [Canada] ; David F. Tang-Wai [Canada] ; Teri Thomsen [Canada] ; Rob M. A. De Bie [Canada, Pays-Bas] ; Pettarusup Wadia [Canada] ; Janis Miyasaki [Canada] ; Sarah Duff-Canning [Canada] ; Anthony E. Lang [Canada] ; Connie Marras [Canada] | A comparison of the mini mental state exam to the montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease |
| 002D92 (2007) |
Teri R. Thomsen [Canada] ; Wendy R. Galpern [Canada, États-Unis] ; Abena Asante [Canada] ; Tamara Arenovich [Canada] ; Susan H. Fox [Canada] | Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease |
| 003143 (2006) |
Susan H. Fox [Canada] ; Anthony E. Lang [Canada] ; Jonathan M. Brotchie [Canada] | Translation of nondopaminergic treatments for levodopa‐induced dyskinesia from MPTP‐lesioned nonhuman primates to phase IIa clinical studies: Keys to success and roads to failure |
| 003277 (2006) |
Naomi P. Visanji [Canada] ; Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Donna Pires [Canada] ; Valerie Voon [Canada, États-Unis] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Pharmacological characterization of psychosis‐like behavior in the MPTP‐lesioned nonhuman primate model of Parkinson's disease |
| 003402 (2006) |
Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Naomi P. Visanji [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | Histamine H3 receptor agonists reduce L‐dopa–induced chorea, but not dystonia, in the MPTP‐lesioned nonhuman primate model of Parkinson's disease |
| 003652 (2006) |
Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Naomi P. Visanji [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of parkinson's disease |
| 003F78 (2003) |
Susan H. Fox ; Anette Nieves [Canada, États-Unis] ; Catherine Bergeron [Canada] ; Anthony E. Lang [Canada] | Pure cerebello‐olivary degeneration of Marie, Foix, and Alajouanine presenting with progressive cerebellar ataxia, cognitive decline, and chorea |
| 004085 (2003) |
Juha-Matti Savola [Finlande] ; Michael Hill [Royaume-Uni] ; Mia Engstrom [Finlande] ; Hannele Merivuori [Finlande] ; Siegfried Wurster [Finlande] ; Steven G. Mcguire [Royaume-Uni] ; Susan H. Fox [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni, Canada] | Fipamezole (JP‐1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa‐induced dyskinesia in the MPTP‐lesioned primate model of Parkinson's disease |
| 004280 (2002) |
Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Michael Hill [Royaume-Uni] ; Alan Crossman [Royaume-Uni] ; Jonathan Brotchie [Royaume-Uni] | Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's disease |
| 004315 (2002) |
Susan H. Fox [Royaume-Uni] ; Mark Kellett [Royaume-Uni] ; A. Peter Moore [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Randomised, double‐blind, placebo‐controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia |
| 004745 (2001) |
Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Micheal P. Hill [Royaume-Uni] ; David Peggs [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Neural mechanisms underlying peak‐dose dyskinesia induced by levodopa and apomorphine are distinct: Evidence from the effects of the alpha2 adrenoceptor antagonist idazoxan |
| 004B66 (2000) |
Susan H. Fox [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | 5‐HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease |
| 004B91 (2000) |
Susan H. Fox [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | 5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease |
| 004C22 (1999) |
Brian Henry [Royaume-Uni] ; Susan H. Fox [Royaume-Uni] ; David Peggs [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | The α2‐adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti‐parkinsonian actions of L‐dopa in the MPTP‐lesioned primate model of Parkinson's disease |
